-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode says preclinical study shows survival benefit for TTX-MC138 in breast cancer bone metastasis model

PUBT·08/31/2026 12:07:35
Listen to the news
TransCode says preclinical study shows survival benefit for TTX-MC138 in breast cancer bone metastasis model
  • TransCode Therapeutics disclosed peer-reviewed preclinical data showing its lead candidate TTX-MC138 extended survival in a breast cancer bone-metastasis mouse model.
  • Study reported drug accumulation in bone lesions following systemic dosing, with reduced miR-10b expression and increased HOXD10 tumor-suppressor expression.
  • Repeated dosing was well tolerated, with no systemic toxicity observed during the study.
  • Results were published online Aug. 23, 2026 in Cancers, supporting potential expansion of miR-10b inhibition into additional metastatic settings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608310805PR_NEWS_USPR_____NE36631) on August 31, 2026, and is solely responsible for the information contained therein.